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Scaling up antiretroviral 
treatment in resource-
poor settings
Anthony  Harries  and  colleagues 
(June 3, p 1870)
1 do well to explore 
the  tensions  between  technical  and 
public-health approaches to the HIV/
AIDS  epidemic  in  Malawi.  However, 
they  miss  opportunities  to  discuss 
several fundamental issues.  
Important lessons could be learned 
from  neighbouring  countries.  In 
Mozambique,  the  antiretroviral 
treatment (ART) scale-up programme 
is very similar to that of Malawi, using 
HIV day hospitals as the focus of care 
for  HIV-positive  people.  However, 
these  specialised  treatment  centres 
for HIV/AIDS have created problems of 
two-way  discrimination.  On  the  one 
hand, many HIV-infected patients are 
reluctant to approach the HIV services 
for fear of discrimination. But on the 
other hand, patients who are not HIV-
positive are silently denied adequate 
general  medical  care  as  resources 
become diverted towards HIV-related 
illnesses.
In  a  country  where  10%  or  more 
of  the  population  are  infected  with 
HIV,  real  scale-up  will  occur  not  by 
simplifying  procedures  as  Harries 
and  colleagues  propose,  but  by 
tackling  the  fundamental  problem  of 
vertical  programmes.  Shouldn’t  we 
be  discussing  decentralised  testing, 
counselling,  and  care  in  peripheral 
health centres and health posts, where 
HIV  services  can  be totally  integrated 
into the primary health-care service and 
as a result begin to overcome the two-
way discrimination that is inevitable in 
vertical ART programmes?
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We  recently  returned  from  a  fact-
ﬁ  nding  mission  in  Malawi  to  assess 
the state of laboratory infrastructure 
and  capabilities  for  monitoring 
antiretroviral  therapy  (ART),  as  part 
of a new initiative at Imperial College 
of Medicine, London, UK, to develop 
simple,  low-cost,  robust,  and  rapid 
tests  for  measuring  CD4  counts  in 
HIV-positive patients in resource-poor 
settings.
What we found on our trip was that 
very  few  facilities  were  doing  CD4 
testing  and  even  the  settings  that 
had  ﬂ  ow  cytometers  on  site  faced 
shortages and interruption of reagent 
supplies,  equipment  breakdown, 
interruption  of  refrigeration  and 
electricity,  and  other  obstacles  that 
will  make  CD4  testing,  and  indeed 
the  use  of  viral  load,  completely 
impractical for the foreseeable future. 
We  therefore  agree  with  Anthony 
Harries and colleagues
1 that adoption 
of  ﬂ  ow  cytometry  and  PCR  for 
monitoring patients on ART will lead 
“to the demise of the country’s ART 
programme”, since a requirement that 
these tests be done on most patients 
is simply unrealistic.
As  part  of  preparations  for  the 
Imperial  CD4  initiative,  we  also  did 
a survey of ART sites in three dozen 
countries around the globe and found 
quite  similar  problems  in  laboratory 
infrastructure and capabilities. To scale 
up ART in the developing world and 
decentralise AIDS  care out of  capital 
cities, the public-health approach used 
in Malawi needs to be adopted more 
widely,  although  each  country  will 
have to ﬁ  nd an approach for delivery 
of  services  that  makes  the  most 
sense given its particular setting and 
available resources.
Integrating  laboratory  monitoring 
in ART programmes will either require 
new  kinds  of  test  that  can  be  done 
without complex instrumentation, by 
non-laboratory staﬀ   (eg, nurses, health 
surveillance assistants), at a very low 
cost,  and  that  can  withstand  the 
environmental conditions prevalent in 
these settings, or a vast improvement 
in  laboratory  infrastructure  and 
capabilities  in  developing  countries, 
both  of  which  conditions  remain 
unmet at the current time. 
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Anthony  Harries  and  colleagues 
provide  a  valuable  contribution  to 
the  debate  on  strategies  for  scaling 
up  antiretroviral  therapy.
1  However, 
we  feel  that  they  overlook  a  critical 
lesson  from the  history  of  HIV/AIDS 
treatment  in  the  developing  world: 
cost  and  complexity  of  treatment 
are  barriers  that  can,  and  must,  be 
challenged. 
The  paper  points to  major threats 
to  sustainable  antiretroviral  roll-out: 
insuﬃ   cient funding and staﬀ  , patient 
overload,  high-cost  medicines,  and 
complexity of laboratory monitoring. 
Although these threats are real, it is 
worth noting that these same threats 
were cited as arguments against scale-
up of ﬁ  rst-line therapy.
2
If  second-line  drugs  are  too 
expensive,  costs  must  be  lowered. 
If  pill  burden  threatens  good 
adherence,  ﬁ  xed-dose  combinations 
and  better  second-line  drugs  must 
be developed. We must advocate for 
tools better adapted to ﬁ  eld realities, 
for  better  staﬀ    salaries,  and  further 
empowerment  of  nurses,  clinical 
oﬃ   cers,  aﬀ  ected  individuals,  and 
communities. These  are  not utopian 
ideals.  According  to  WHO,  Chinese 
generic  antiretrovirals  could  render 
second-line  treatment  as  aﬀ  ordable 
as  ﬁ  rst-line;
3  further  ﬁ  xed-dose 
combinations are in development, and 
simpliﬁ  ed methods of measuring CD4 
count
4  and  viral  load
5  are  becoming 
available. 
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We  wholeheartedly  endorse  the 
call  for  simplicity  to  maximise 
access to essential health care in the 
face  of  limited  resources.  First-line 
rollout  is  the  priority,  but  barriers 
that  exclude  access  to  second-line 
drugs must not be taken for granted. 
Aﬀ  ordable,  two-pills-a-day  triple 
therapy  is  only  available  thanks 
to  strong  political  advocacy  and  a 
refusal  to  accept  that  antiretroviral 
therapy was unattainable. The same 
logic,  however  idealistic  it  might 
currently  seem,  must  be  applied to 
ensure that patients for whom ﬁ  rst-
line treatment fails are not denied a 
second chance.
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Coordinating HIV 
control eﬀ  orts
Roger England (May 27, p 1786)
1 is right 
to press for more accountability and a 
stronger focus of resources on priorities. 
But  he  is  inconsistent  in  laying  the 
blame for many of the missed priorities 
and  wasted  eﬀ  orts  on  national  AIDS 
commissions  (NACs),  when  in  reality 
the bulk of resources do not go through 
the hands of NACs at all. He seems to 
point the ﬁ  nger of blame only at the 
failure  of  national  public  institutions, 
and  not  see  the  challenges  posed  by 
the practices of international partners 
in  a  crowded  institutional  landscape. 
Privatisation as suggested by England 
in  low-capacity  countries  does  not 
guarantee better performance.
We  suggest  what  is  needed  is  for 
national  AIDS  authorities  to  develop 
prioritised and costed AIDS plans that 
are aligned with national development 
plans,  with  the  goal  of  scaling  up 
towards universal access to prevention, 
treatment,  care  and  support.  Civil 
society  and  vulnerable  groups  should 
be fully engaged in developing national 
plans, and countries should ensure the 
account ability  of  all  partners  through 
transparent  peer  review  mechanisms 
for  monitoring  of  processes  and 
targets. 
We  must  be  more  rigorous  in 
applying  existing  commitments:    the 
Three Ones Principles,
2 the Global Task 
Team  Recommendations,
3  and  the 
Paris Declaration.
4 At country level, the 
AIDS  response  is  often  complex  and 
fragmented. Without a clearer focus on 
harmonising the disparate players and 
resources,  and  aligning  these  behind 
the  single  national  response,  simply 
contracting out the NAC functions will 
not  address  this  fragmentation,  and 
will  impede  our  aspiration  to  most 
eﬀ  ectively  scale  up  towards  universal 
access.
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Russia, the G8, and HIV
Although  it  is  true  that  Russia’s 
HIV  epidemic  is  moving  into  the 
general population (May 27, p 1703),
1 
Russian reluctance to address issues 
related  to  injection  drug  use  will 
probably  stymie  eﬀ  orts  to  achieve 
either  eﬀ  ective  HIV  prevention 
or  the  universal  access  to  HIV 
medications  promised  by  2008. 
Although  the  Russian  government 
has increased its support for sterile 
syringe  programmes,  coverage 
still  falls  far  below what  is  needed.
Medications  that  block  craving  for 
illicit opiates such as methadone and 
buprenorphine,  proven  to  reduce 
HIV  risk  behaviours  and  improve 
adherence  to  HIV  medications, 
remain  unavailable.  And  vertical 
systems  of  care  and  provider 
prejudice  mean  that  injecting  drug 
users—the overwhelming majority of 
Russians living with HIV—are shunted 
from one clinic to another.
Even  the  generalisation  of  the 
epidemic is a mark of the reluctance 
to provide services to drug users and 
their  families,  since  sexual  health 
programmes  that  recognise  the 
realities of drug users’ lives have been 
lacking.
President Putin’s new willingness to 
engage the HIV issue is most welcome. 
But  the  Russian  government  and 
international actors such as the Global 
Fund  will  have  to  work  to  ensure 
that  this  translates  into  services  for 
injecting  drug  users,  rather  than 
rhetoric that encourages G8 members 
without  improving  the  lot  of  most 
Russians with HIV.
The International Harm Development Program 
directly funds harm reduction programmes in the 
former Soviet Union.
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